CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Open-market sale President and CEO sold 217,515 shares at an average $15.35 ($3,338,725)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale SVP & Chief Commercial Officer sold 881 shares at an average $20.04 ($17,655)
- 4 Open-market sale President and CEO sold 44,666 shares at an average $19.53 ($872,226)
- 4 Open-market sale EVP & Chief Financial Officer sold 13,727 shares at an average $19.98 ($274,233)
- 4 Open-market sale SVP, Business Development sold 12,529 shares at an average $19.96 ($250,092)
- 4 Grant or award SVP & General Counsel acquired 30,000 shares (grant or award)
- 4 Grant or award SVP & Chief Commercial Officer acquired 30,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 60,000 shares (grant or award)
- 4 Grant or award EVP & Chief Financial Officer acquired 30,000 shares (grant or award)
- 4 Grant or award SVP, Business Development acquired 30,000 shares (grant or award)
- 4 Open-market sale SVP & Chief Commercial Officer sold 1,130 shares at an average $26.59 ($30,042)
- 4 Open-market sale SVP, Business Development sold 6,061 shares at an average $26.37 ($159,810)
- 4 Open-market sale EVP & Chief Financial Officer sold 6,061 shares at an average $26.37 ($159,811)
- 4 Open-market sale President and CEO sold 15,236 shares at an average $26.36 ($401,663)
- 4 Grant or award SVP & General Counsel acquired 30,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 10 of 29 · 579 filings